Jefferies Financial Group Analysts Reduce Earnings Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Jefferies Financial Group reduced their FY2021 earnings per share estimates for shares of Halozyme Therapeutics in a report released on Monday, January 10th. Jefferies Financial Group analyst E. Yang now expects that the biopharmaceutical company will earn $1.80 per share for the year, down from their previous forecast of $1.86. Jefferies Financial Group also issued estimates for Halozyme Therapeutics’ Q1 2022 earnings at $0.41 EPS, Q2 2022 earnings at $0.51 EPS, Q3 2022 earnings at $0.57 EPS, Q4 2022 earnings at $0.48 EPS, FY2022 earnings at $1.97 EPS and FY2023 earnings at $3.18 EPS.

Several other research analysts also recently commented on the company. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $60.00 to $58.00 and set an “overweight” rating for the company in a research note on Wednesday, November 24th. TheStreet upgraded Halozyme Therapeutics from a “c+” rating to a “b” rating in a research note on Monday, September 20th. JMP Securities reiterated a “buy” rating and set a $54.00 target price on shares of Halozyme Therapeutics in a research note on Friday, December 10th. lifted their target price on Halozyme Therapeutics from $27.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, December 2nd. Finally, SVB Leerink reduced their target price on Halozyme Therapeutics from $50.00 to $48.00 and set an “outperform” rating for the company in a research note on Wednesday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $51.25.

Shares of NASDAQ HALO opened at $35.56 on Thursday. The company has a current ratio of 8.99, a quick ratio of 8.50 and a debt-to-equity ratio of 2.79. Halozyme Therapeutics has a 12 month low of $31.79 and a 12 month high of $56.40. The stock has a 50 day moving average of $36.70 and a 200-day moving average of $39.60. The company has a market capitalization of $5.01 billion, a P/E ratio of 12.75 and a beta of 1.30.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, November 2nd. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.42 by $1.06. The firm had revenue of $115.83 million during the quarter, compared to the consensus estimate of $101.94 million. Halozyme Therapeutics had a return on equity of 187.85% and a net margin of 88.36%. During the same period last year, the company earned $0.25 earnings per share.

In other Halozyme Therapeutics news, CEO Helen Torley sold 50,000 shares of Halozyme Therapeutics stock in a transaction on Monday, November 8th. The stock was sold at an average price of $39.82, for a total value of $1,991,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Connie Matsui sold 32,000 shares of Halozyme Therapeutics stock in a transaction on Friday, November 5th. The shares were sold at an average price of $40.38, for a total value of $1,292,160.00. The disclosure for this sale can be found here. 2.60% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the company. Synovus Financial Corp raised its holdings in shares of Halozyme Therapeutics by 19.9% during the 3rd quarter. Synovus Financial Corp now owns 61,400 shares of the biopharmaceutical company’s stock worth $2,495,000 after buying an additional 10,181 shares in the last quarter. Swiss National Bank raised its holdings in shares of Halozyme Therapeutics by 5.5% during the 3rd quarter. Swiss National Bank now owns 298,900 shares of the biopharmaceutical company’s stock worth $12,159,000 after buying an additional 15,600 shares in the last quarter. Amundi acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $335,000. New York State Common Retirement Fund raised its holdings in shares of Halozyme Therapeutics by 8.3% during the 3rd quarter. New York State Common Retirement Fund now owns 1,749,309 shares of the biopharmaceutical company’s stock worth $71,162,000 after buying an additional 133,986 shares in the last quarter. Finally, Securian Asset Management Inc raised its holdings in shares of Halozyme Therapeutics by 3.0% during the 2nd quarter. Securian Asset Management Inc now owns 12,300 shares of the biopharmaceutical company’s stock worth $559,000 after buying an additional 355 shares in the last quarter. 90.56% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Article: What moving averages are used to define a golden cross?

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.